Wockhardt hosts Prince Charles at its Wrexham facility in UK

Published On 2021-07-06 06:30 GMT   |   Update On 2021-07-06 09:33 GMT

New Delhi: Drug firm Wockhardt on Monday welcomed Prince Charles to its Wrexham manufacturing facility in the UK.Wockhardt UK specialises in the manufacture of sterile injectables and is one of the largest generic pharmaceutical companies in the UK with the capability to manufacture on a large scale, Wockhardt said in a regulatory filing.Wockhardt UK has been instrumental in the manufacture...

Login or Register to read the full article

New Delhi: Drug firm Wockhardt on Monday welcomed Prince Charles to its Wrexham manufacturing facility in the UK.

Wockhardt UK specialises in the manufacture of sterile injectables and is one of the largest generic pharmaceutical companies in the UK with the capability to manufacture on a large scale, Wockhardt said in a regulatory filing.

Wockhardt UK has been instrumental in the manufacture of the Oxford-AstraZeneca COVID-19 vaccine and carries out the ''fill and finish'' stage of the vaccine manufacturing process, it added.

"The visit on Monday by His Royal Highness The Prince of Wales demonstrates recognition of our global strength in sterile injectable facilities and capacity," Wockhardt Founder Chairman Habil Khorakiwala said.

Read also: Wockhardt at the forefront of UK vaccination: Report

The company is one of the major suppliers to the National Health Service (NHS) and has a site in Wrexham for over 20 years, Wockhardt said.

"We are delighted to showcase our innovation, talent and expertise at Wockhardt UK to His Royal Highness," Wockhardt MD and Global CEO Murtaza Khorakiwala said.

Read also: Wockhardt reports PAT at Rs 15 crore in Q3



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News